NCT03414229: A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma |
|
|
| Active, not recruiting | 2 | 30 | US | Epacadostat, Pembrolizumab | Memorial Sloan Kettering Cancer Center, Incyte Corporation, Merck Sharp & Dohme LLC, M.D. Anderson Cancer Center | Sarcoma | 01/25 | 01/25 | | |
